“a favorable trend”

Combined immunotherapy and antiangiogenic therapy also showed a favorable trend compared to Sunitinib regarding objective response rate (OR=2.53 (2.23, 2.87), P < 0.00001) (Figure 4 ).

The incidence was 7.9% (79 of 994) in statin group and 14% (140 of 992) in control group, demonstrating that high-dose statin therapy preloading before PCI had a favorable trend toward the following outcome and reduced the incidence of MACE (OR=0.53, 95% CI: 0.39 to 0.71, p<0.0001) ( Figure 5 ).

The results suggest a favorable trend in PFS for the patients treated with icotinib+chemotherapy compared to those treated with icotinib alone ( p <0.001, Figure 1A ).

Patients with MLH1/MSH2 -negative stage II or III CRC showed a favorable trend for OS (68.62 ± 0.83 vs 62.11 ± 1.07 mo, P < 0.001).

In the stratified analysis of study design, a favorable trend still existed in non-RCTs, with an RR of 3.68 and 95% CI [2.34–5.79] ( P < 0.001, fixed-effects model).

However, the comparison between groups showed a favorable trend in the OB group in comparison with placebo, with significant differences at week 10 and week 15 by ANOVA and at week 15 by GLM ( p = 0.002) ( Figure 3 ).

For both approaches, serious complications demonstrated a favorable trend: laparoscopic CBS serious complications decreased from 6.39% in 2020 to 5.64% in 2022 ( p = 0.002), while robotic CBS serious complications decreased from 7.64% in 2020 to 6.14% in 2022 ( p = 0.009).

Meta-analysis In the meta-analysis performed, when only the internal gap [ Figure 2 ] was evaluated, there was a statistically significant difference with a favorable trend in the press technique (DM = 70.51, 95% CI: 25.45–115.58, P = 0.002).

Notably, 12 weeks of probiotics intake demonstrated a favorable trend on social engagement (SMD −0.68; 95% CI: −1.14 to −0.21; p = 0.004).

In addition, both overall survival and leukemia-free survival rates showed a favorable trend toward the CAR T-cell+SCT group, respectively (hazard ratio, 0.44; 95% CI, 0.25–0.77; P =0.005; I 2 =0%; evidence, low; and hazard ratio, 0.29; 95% CI, 0.17–0.49; P <0.00001; I 2 =0%; evidence, low).

In the Cox hazard analysis adjusted with IPW, Dur/Tre demonstrated a favorable trend in OS (hazard ratio [HR] <0.75) in patients with elevated alpha-fetoprotein (AFP) (≥100 ng/mL) (HR 0.72, interaction p = 0.006) or double positive elevation of tumor marker (AFP and des-gamma-carboxy prothrombin [≥100 mAU/mL]) (HR 0.66, interaction p = 0.005).

Most subgroups benefited from nivolumab plus chemotherapy compared with chemotherapy alone, and the interim analysis showed a favorable trend for OS (HR = 0.57; p = 0.0079).

Cumulative survival at 24 months remained stable (periods 1989–1998, 1999–2001, 2002–2008, 2009–2011, 2012–2015, 2016–2019 were each 72.0%, 72.9%, 77.7%, 83.0%, 84.9%, 83.5%, p < 0.01), while renal survival showed a favorable trend in the most recent periods (there were each 68.7%, 75.4%, 76.7%, 73.4%, 78.2%, 78.4%, p < 0.01).

Time-to-potency recovery, while showing a favorable trend for ultrapreservation ( p = 0.012), did not reach statistical significance after multiple comparison adjustment.

Although this indicated a favorable trend towards pain reduction, the difference did not meet the adjusted statistical significance threshold ( p < 0.0125) following the Bonferroni correction ( Figure 3 ). 4.

In the larger phase 2b trial ( n = 248, 26 weeks), cotadutide 300–600 μg daily achieved dose-dependent reductions in UACR (− 44% to − 50%) and a favorable trend in eGFR slope at the highest dose ( P = 0.016) compared with placebo.

In addition, a favorable trend was found for diastolic blood pressure with CAD in the intervention group (time and group interaction, p = 0.017).

In addition, the patients with WT KRAS with a favorable trend (n=11) showed a median PFS of 14.7 months, higher than that of the patients with WT KRAS with unfavorable kinetics (n=9), of 9.4 months ( P =0.02; Figure 6 ).

Even the combined-endpoint favorable ventricular remodeling associated with functional improvement ( Figure 2 , Table 4 ) showed a favorable trend (log rank test p = 0.02) in non-ischemic patients, not reaching the statistical significance after adjusting for age and sex (HR: 0.17; 95% CI: 0.02–1.49; p = 0.109).

A favorable trend was observed in case of RTV <10 cm 3 that was obtained in about 70% of patients (p=0.03).

Physical activity retained a favorable trend (model 1: OR = 0.61, p = 0.030).

A favorable trend in OS in the pembrolizumab group was also observed (HR 0.72, 95% CI 0.51-1.02; P=0.03) ( 42 ).

Compared with group B (IMRT alone), group A (IMRT plus sorafenib) displayed a favorable trend in median OS (11.0 versus 9.0 months, P =0.036), 1 yr and 2 yrs OS (44.9% versus 28.6% and 3.8% versus 2.6%), median PFS (6.0 versus 3.0 months, P =0.012), 1 yr and 2 yrs PFS (20.7% versus 2.7% and 6.9% versus 0.0%).

36.7 months for chemotherapy, but the pre-specified alpha of 0.025 required for statistical significance was not reached, so superiority of pembrolizumab over chemotherapy in OS was not statistically demonstrated, although a favorable trend was observed (HR = 0.74, 95% CI: 0.53–1.03, p = 0.036) [ 59 ].

15.2 months; hazard ratio [HR], 0.64) and showed a favorable trend in OS (50.8 vs. 43.6 months; HR, 0.78; P = 0.042) compared with carfilzomib and dexamethasone (Kd), particularly in high-risk cytogenetics (34.3 vs. 17.1 months; HR, 0.52) and lenalidomide- and PI-refractory patients.